Study to Assess Cardiac Conduction of GSK1349572

Exclusion Criteria

• •The subject has a positive pre-study drug/alcohol screen.
• •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• •History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy.
• •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days prior to the first dose of study medication.
• •If heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
• •History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of \>14 drinks/week for men or \>7 drinks/week for women.
• •Has a history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
• •Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
• •Pregnant females as determined by positive serum or urine human chorionic gonadotrophin (hCG) test at screening or prior to dosing.
• •Lactating females.
• •Unwillingness or inability to follow the procedures outlined in the protocol.
• •Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy, inflammatory bowel disease or pancreatitis should be excluded.
• •Subjects with active peptic ulcer disease.
• •Subjects with a history of upper gastrointestinal bleeding,
• •History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease. Personal or family history of long QT syndrome.
• •History/evidence of clinically significant pulmonary disease.
• •History of significant renal or hepatobiliary diseases. Subjects with a history of nephrolithiasis will be excluded.
• •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• •A positive test for HIV antibody.
• •History of 2nd degree or higher AV block.
• •History of Gilbert's disease.
• •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• •Subjects with a hemoglobin \<12 g/dL.
• •The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects or 45-100 bpm for male subjects.
• •ECG within protocol limits.